XERS — XERIS PHARMACEUTICALS INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
XERS FAQ
What is XERS's P/E ratio?
XERIS PHARMACEUTICALS INC (XERS) currently trades at a P/E ratio of 83.12.
What is XERS's ROE?
XERIS PHARMACEUTICALS INC reports a Return on Equity (ROE) of 92.29%.
What is XERS's dividend yield?
XERIS PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is XERS's Deepscope Quality Score?
Deepscope rates XERS's overall financial quality at 69 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy XERS?
Deepscope's AI Timing Score for XERS is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does XERS belong to?
XERIS PHARMACEUTICALS INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.
|
USD 6.93
Price
-0.14
(-2.02%)
Day Change
|
|
|---|
XERS Chất lượng tổng thể của cố phiếu Khá ( Chất lượng = 69) và Thời điểm mua ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Tỷ lệ P/E tương đối cao
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt lắm , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
3113
|
| Magic Formula Rank by ROE |
3113
|
| Magic Formula Rank by ROIC |
3115
|
| Price | 6.93 |
| PBV / Sector |
89.03 / 2.57
|
| Earning Per Share | 0.07 |
| PE / Sector |
83.12 / 24.33
|
| PEG or PE/Growth / Sector |
-1.63 / 0.12
|
| Average 1M Daily Value |
9.12 M
|
| Average 1W Daily Value |
12.45 M
GREAT
|
| Yếu tố Kỹ thuật |
|
71% |
| Sức khỏe tài chính |
|
41% |
| Khả năng kiếm lợi nhuận |
|
58% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-12 09:43:44 |
| Symbol | XERS |
| Name | XERIS PHARMACEUTICALS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 172.64 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,158.43 / 9,929.32 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1375 West Fulton Street, Chicago, IL, United States, 60607
Phone: 844 445 5704
Website: https://www.xerispharma.com
Employees: 435
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google